TSXV:CDX

Cloud DX Awarded Silver at the 2021 Edison Awards

Cloud DX (TSXV:CDX) a leading provider of virtual care and remote patient monitoring solutions, is delighted to announce that its breakthrough VITALITI™ continuous vital sign monitor platform has earned a Silver 2021 Edison Award in the Science, Medical & Dental IoT category. The Edison Awards has been recognizing and honoring the best in technological innovation across the globe since 1987

The VITALITI™ continuous vital sign monitor is among the most advanced medical wearables ever designed, continuously measuring ECG, heart rate, oxygen saturation, respiration, core body temperature, non-invasive blood pressure, movement, steps and posture. When fully commercialized VITALITI™ will be the first of its kind as a portable, wearable, scientifically validated, medical-grade continuous vital sign monitor for post-operative hospital-to-home patient care. VITALITI™ was originally developed as part of the Team Cloud DX entry in the Qualcomm Tricorder® XPRIZE competition, where the company was awarded the first ever Bold Epic Innovator Award for "exponential technological progress in the field of consumer-focused medical technologies with the greatest potential for expanding access to healthcare when deployed at scale."

The Edison Award builds on Cloud DX's established track record for innovation recognition. In addition to the XPRIZE, VITALITI™ has been named a Fast Company "World Changing Idea" and BNN "Top Disruptor."

"More than 230 million adults have major non-cardiac surgery annually and over 25% of those adults over the age of 45 will suffer a major complication (myocardial infarction, bleeding, sepsis and infection) in the first 30 days post-operative days. This critical medical challenge, coupled with our mission to make healthcare better for everyone inspired the creation of VITALITI. Simply put, this technology was designed from the ground up to save lives," says Robert Kaul, CEO of Cloud DX. "We are thrilled by the global recognition we have received from the Edison Awards team, and we are humbled to stand alongside exceptional household name brands such as Medtronic, SC Johnson, Avon and Abbott and to have our brand associated with Thomas Edison, one of the most celebrated inventors of all time."

Cloud DX's VITALITI™ was selected by a panel of judges comprised of more than 3,000 leading business executives and academics from around the world. "All around this year we've seen more intensity in the medical, science, and engineering categories as companies seek solutions for this changing world," said Frank Bonafilia, executive director of the Edison Awards. "After a thorough review, the Edison Awards judges recognized the VITALITI™ as a game-changing innovation, standing out in the Science, Medical & Dental: IoT category."

Cloud DX

Accelerating virtual healthcare's future, Cloud DX is making healthcare better for everyone. The company's Connected Health remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place and deliver hospital-quality post-surgical care. Providers partnering with Cloud DX achieve better healthcare and patient outcomes, reduce the need for hospitalization/re-hospitalization and reduce the costs of healthcare delivery through more efficient use of resources. In addition to being an Edison Award winner, Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a Fast Company "World Changing Idea" finalist and one of Canada's 10 most prominent Telehealth providers.

Edison Awards

Over the last 34 years, being recognized with an Edison Award has become one of the highest accolades a product can receive in the name of innovation success. The awards are named after Thomas Alva Edison (1847-1931) whose inventions, new product development methods, and innovative achievements changed the world. The Edison Awards are operated by Edison Universe, a 501(c)(3) non-profit organization with the mission of recognizing, honoring and fostering innovations and innovators, and are hosted in Fort Myers, Florida.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Social Links

Twitter: https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/

For media inquiries please contact:

Ellyn Winters-Robinson
Ignition Communications (PR for Cloud DX)
519-574-2196
ellyn@ignition.ca

For investor inquiries please contact:

Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com

Cloud DX Corporate Contact

Robert Kaul
CEO
1-646-706-1807
Robert.kaul@clouddx.com

SOURCE:Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/641942/Cloud-DX-Awarded-Silver-at-the-2021-Edison-Awards

News Provided by ACCESSWIRE via QuoteMedia

The Conversation (0)
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Zero Candida Technologies Inc.  Opens the Market

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
XReality Group

xReality Group Limited Chairman’s Address 2024 Annual General Meeting – 22 November 2024

xReality Group Limited (ASX:XRG) (xReality) is pleased to present xReality Group Limited’s 2024 Annual General Meeting.

Keep reading...Show less
XReality Group

Operator XR – Sales Update November 24

xReality Group Limited (ASX:XRG) (xReality) is pleased to provide the following sales update for Operator XR, a wholly owned subsidiary of xReality Group Ltd. Operator XR provides Military and Law Enforcement agencies around the world with a unique, integrated Mission Planning & Rehearsal System, which is portable, secure, and highly immersive.

Keep reading...Show less

Latest Press Releases

Related News

×